ALPCO Launches Antibodies Supporting Pancreatic Cancer Research
Summary
Recent “ALPCO is addressing these issues by now providing well characterized antibodies that can be used to advance pancreatic research,” says ALPCO’s President, Sean Conley.Advancements have been made in regards to identifying extracellular markers specific to pancreatic cell subtypes, consisting of monoclonal antibodies that recognize the surface of endocrine, alpha, duct and acinar cells.For more information about ALPCO’s new panel of pancreatic antibodies, visit About ALPCO ALPCO (American Laboratory Products Company) was founded in 1991 as a provider of immunoassay kits for the North American research markets.Current projections show that pancreatic cancer will become the second-leading cause of cancer-related deaths in the U.S. by the year 2030.The research community is in need of reliable tools to analyze and understand the molecular mechanisms of pancreatic cancer to combat its steadily increasing growth.“ALPCO is addressing these issues by now providing well characterized antibodies that can be used to advance pancreatic research,” says ALPCO’s President, Sean Conley.Advancements have been made in regards to identifying extracellular markers specific to pancreatic cell subtypes, consisting of monoclonal antibodies that recognize the surface of endocrine, alpha, duct and acinar cells.For more information about ALPCO’s new panel of pancreatic antibodies, visit http://www.alpco.com/products/Pancreatic_Antibodies.aspx About ALPCOALPCO (American Laboratory Products Company) was founded in 1991 as a provider of immunoassay kits for the North American research markets.